2型糖尿病および慢性腎臓病患者におけるセマグルチドの有効性をプラセボと比較する研究

基本情報

NCT ID

NCT03819153

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

3,533

治験依頼者名

Novo Nordisk A/S

概要

The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will get semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer.

対象疾患

介入

依頼者（Sponsor）

実施施設 (26)